204 related articles for article (PubMed ID: 29389804)
1. Norleual, a hepatocyte growth factor and macrophage stimulating protein dual antagonist, increases pancreatic cancer sensitivity to gemcitabine.
Church KJ; Vanderwerff BR; Riggers RR; Mateo-Victoriano B; Fagnan M; Harris PH; LeValley JC; Harding JW
Anticancer Drugs; 2018 Apr; 29(4):295-306. PubMed ID: 29389804
[TBL] [Abstract][Full Text] [Related]
2. Analogs of the hepatocyte growth factor and macrophage-stimulating protein hinge regions act as Met and Ron dual inhibitors in pancreatic cancer cells.
Church KJ; Vanderwerff BR; Riggers RR; McMicheal MD; Mateo-Victoriano B; Sukumar SR; Harding JW
Anticancer Drugs; 2016 Sep; 27(8):766-79. PubMed ID: 27314431
[TBL] [Abstract][Full Text] [Related]
3. Hepatocyte Growth Factor and Macrophage-stimulating Protein "Hinge" Analogs to Treat Pancreatic Cancer.
Wright JW; Church KJ; Harding JW
Curr Cancer Drug Targets; 2019; 19(10):782-795. PubMed ID: 30914029
[TBL] [Abstract][Full Text] [Related]
4. Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer.
Pothula SP; Xu Z; Goldstein D; Biankin AV; Pirola RC; Wilson JS; Apte MV
Br J Cancer; 2016 Feb; 114(3):269-80. PubMed ID: 26766740
[TBL] [Abstract][Full Text] [Related]
5. Mimics of the dimerization domain of hepatocyte growth factor exhibit anti-Met and anticancer activity.
Kawas LH; Yamamoto BJ; Wright JW; Harding JW
J Pharmacol Exp Ther; 2011 Nov; 339(2):509-18. PubMed ID: 21859930
[TBL] [Abstract][Full Text] [Related]
6. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642
[TBL] [Abstract][Full Text] [Related]
7. Comparative characterization of the HGF/Met and MSP/Ron systems in primary pancreatic adenocarcinoma.
Vanderwerff BR; Church KJ; Kawas LH; Harding JW
Cytokine; 2019 Nov; 123():154762. PubMed ID: 31254927
[TBL] [Abstract][Full Text] [Related]
8. The angiotensin IV analog Nle-Tyr-Leu-psi-(CH2-NH2)3-4-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor.
Yamamoto BJ; Elias PD; Masino JA; Hudson BD; McCoy AT; Anderson ZJ; Varnum MD; Sardinia MF; Wright JW; Harding JW
J Pharmacol Exp Ther; 2010 Apr; 333(1):161-73. PubMed ID: 20086056
[TBL] [Abstract][Full Text] [Related]
9. Nicotine Reduces Survival via Augmentation of Paracrine HGF-MET Signaling in the Pancreatic Cancer Microenvironment.
Delitto D; Zhang D; Han S; Black BS; Knowlton AE; Vlada AC; Sarosi GA; Behrns KE; Thomas RM; Lu X; Liu C; George TJ; Hughes SJ; Wallet SM; Trevino JG
Clin Cancer Res; 2016 Apr; 22(7):1787-99. PubMed ID: 26667487
[TBL] [Abstract][Full Text] [Related]
10. Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival.
Ogura Y; Mizumoto K; Nagai E; Murakami M; Inadome N; Saimura M; Matsumoto K; Nakamura T; Maemondo M; Nukiwa T; Tanaka M
Cancer Gene Ther; 2006 May; 13(5):520-9. PubMed ID: 16341142
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M
Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.
Chen D; Niu M; Jiao X; Zhang K; Liang J; Zhang D
Int J Mol Sci; 2012; 13(1):1186-1208. PubMed ID: 22312312
[TBL] [Abstract][Full Text] [Related]
13. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
[TBL] [Abstract][Full Text] [Related]
14. The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer.
Hashim YM; Vangveravong S; Sankpal NV; Binder PS; Liu J; Goedegebuure SP; Mach RH; Spitzer D; Hawkins WG
J Exp Clin Cancer Res; 2017 Jan; 36(1):14. PubMed ID: 28095907
[TBL] [Abstract][Full Text] [Related]
15. Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer.
Song B; Liu XS; Rice SJ; Kuang S; Elzey BD; Konieczny SF; Ratliff TL; Hazbun T; Chiorean EG; Liu X
Mol Cancer Ther; 2013 Jan; 12(1):58-68. PubMed ID: 23188630
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
17. Development of angiotensin IV analogs as hepatocyte growth factor/Met modifiers.
Kawas LH; McCoy AT; Yamamoto BJ; Wright JW; Harding JW
J Pharmacol Exp Ther; 2012 Mar; 340(3):539-48. PubMed ID: 22129598
[TBL] [Abstract][Full Text] [Related]
18. RC-3095, a gastrin-releasing peptide receptor antagonist, synergizes with gemcitabine to inhibit the growth of human pancreatic cancer CFPAC-1 in vitro and in vivo.
Hong SK; Yang SY; Yin SH; Yang KX
Pancreas; 2014 Jan; 43(1):15-21. PubMed ID: 24326363
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
[TBL] [Abstract][Full Text] [Related]
20. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.
DeRosier LC; Huang ZQ; Sellers JC; Buchsbaum DJ; Vickers SM
J Gastrointest Surg; 2006 Nov; 10(9):1291-300; discussion 1300. PubMed ID: 17114015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]